Xcout Intel
Granite Bio
Granite Bio is a biotechnology company headquartered in Basel, Switzerland. It is developing first-in-class therapies by targeting fundamentals of biology and debuted with $100 million of capital.
Subscribe to see Granite Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Granite Bio at a glance
Granite Bio is a biotech company headquartered in Switzerland. Xcout tracks 15 named people at Granite Bio, including Patrick Loustau (President and Chief Executive Officer).
Granite Bio leadership
- Patrick LoustauPresident and Chief Executive Officer
- Dominik HartlChief Medical Officer
- Gijs van den BrinkChief Scientific Officer
- Thomas HuberChief Development Officer
- Anja HippHead of CMC, VP
- Jean-Nicolas SchickelHead Immunology Discovery, VP
9 more named people on record for Granite Bio, with roles, board committees and tenure — see the full roster →
Granite Bio competitors
A few of Granite Bio's closest competitors — see the full list of competitors and alternatives →
Vaderis Therapeutics AG is a clinical-stage biotechnology company focused on developing novel treatments for severe vascular diseases. The company is headquartered in Basel, Switzerland.
Mysthera Therapeutics AG is a biotechnology company headquartered in Basel, Switzerland, focused on developing first-in-class, oral therapeutics to treat inflammation-driven and related diseases.
Windward Bio is a clinical-stage biotechnology and drug development company headquartered in Basel, Switzerland. It is committed to improving outcomes for people living with serious immunological diseases through its deep discovery, development, and commercialization expertise.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Amporin Pharmaceuticals AG is a Swiss biotechnology company founded in Basel in 2024. The firm focuses on developing a new class of small-molecule drugs designed to target toxic membrane mechanisms.
Get Granite Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Granite Bio in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access